Organization (Industry)
Mateon Therapeutics (United States)
ClinicalTrials.gov lists Mateon Therapeutics (United States) as lead sponsor of 14 trials. It has 5 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Mateon Therapeutics (United States): 14 lead-sponsored trials and 1 legal-entity registration.
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 2 |
| Choroidal Neovascularization | 2 |
| Head and Neck Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Neoplasm Metastasis | 2 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2020 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 3 |
| 2009 | 2 |
| 2008 | 1 |
| 2007 | 1 |
| 2006 | 1 |
| 2005 | 3 |
Recruitment duration, a model prediction: none of the 14 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (5)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| DEXAMETHASONE | 1 |
| Artemisinin | 1 |
| CARBOPLATIN | 2 |
| (nab)-paclitaxel | 2 |
| BEVACIZUMAB | 2 |
Journals published in (15)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cancer research | 2 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 2 |
| Anticancer research | 1 |
| Bioorganic & medicinal chemistry | 1 |
| Cancer | 1 |
Showing 5 of 15 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 29 | 1 | 2022-08-23 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | 249,279,832 | 4,357 |
| 2024 | not reported | -4,523,932 | not reported |
| 2023 | 70,000 | -7,903,093 | 61,143 |
| 2022 | not reported | 5,094,981 | 756,910 |
| 2021 | not reported | -9,391,042 | 3,658,617 |
| 2020 | 1,740,855 | -9,502,602 | 4,302,447 |
| 2019 | not reported | -6,638,013 | 1,372,151 |
| 2018 | not reported | -712,738 | 649,755 |
| 2017 | not reported | -13,812,000 | 10,471,000 |
| 2016 | not reported | -13,654,000 | 8,764,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (69)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-08-03 | Debt financing | not disclosed | Sec extracted |
| 2026-07-10 | Other financing | not disclosed | Sec extracted |
| 2026-06-23 | Debt financing | 178,410 | Sec extracted |
| 2026-05-01 | Other financing | not disclosed | Sec extracted |
| 2026-04-30 | Other financing | not disclosed | Sec extracted |
Showing 5 of 69 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Novartis Ag | Co sponsors trial with | 1 |
| Roche (Switzerland) | Co sponsors trial with | 1 |
| University of Washington | Co sponsors trial with | 1 |
| East and North Hertfordshire NHS Trust | Co sponsors trial with | 1 |
| The Christie NHS Foundation Trust | Co sponsors trial with | 1 |
Latest dated events (117)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-03 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-10 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-23 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-01 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-04-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 117 events.
Biomarker capability evidence (43)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CHGA | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 43 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.